Emitefur

Subscribe to Selected New Research on Emitefur

22 relevant articles (3 outcomes, 2 trials/studies) found for this Bio-Agent

Description: structure given in first source

Also Known As:

3 (3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxymethyl-5-fluorouracil; BOF A2; BOF-A2; Benzoic acid, 3-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)-, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Experts

1.	Corey, A: 1 article (10/2000)
2.	Hoff, P M: 1 article (10/2000)
3.	Eager, R: 1 article (10/2000)
4.	Nemunaitis, J: 1 article (10/2000)
5.	Twaddell, T: 1 article (10/2000)
6.	Thompson, J: 1 article (10/2000)
7.	Tkaczuk, K: 1 article (10/2000)
8.	Sekar, K: 1 article (10/2000)
9.	Pazdur, R: 1 article (10/2000)
10.	Sugimachi, K: 1 article (01/2000)

Related Diseases

1.	Stomach Neoplasms (Stomach Cancer) 08/01/1994 - "The combination therapy of BOF-A2 with CDDP was effective against stomach cancer (H-111) from the cellular change and decreased side effect" 01/01/2000 - "Based on the above findings, BOF-A2 is considered to be a promising anticancer drug for patients with advanced gastric cancer." 08/01/1994 - "The combination therapy of BOF-A2 with MMC showed additive effect against stomach cancer (H-111) from IR and cellular changes" 01/01/2000 - "The antineoplastic effects of BOF-A2 (Emitefur), a 5-fluorouracil (5-FU) derivative, in capsule form were assessed in patients with advanced gastric cancer, in a multicenter late phase II study and at 11 different hospitals" 01/01/2000 - "A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer." Get all the results and reference details, order at left...
2.	Small Cell Carcinoma (Small Cell Lung Cancer) 01/01/1994 - "Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer" 01/01/1994 - "Oral BOF-A2 (Emitefur), a new derivative of 5-fluorouracil (5-FU) containing both 1-ethoxymethyl-5-FU (EMFU), a masked form of 5-FU, and 3-cyano-2,6-dihydroxypyridine (CNDP), an inhibitor of 5-FU degradation, was administered to 71 non-small cell lung cancer (NSCLC) patients in a multi-center phase II study" Get all the results and reference details, order at left...
3.	Colorectal Neoplasms (Colorectal Cancer) 07/01/1994 - "We investigated the effects of BOF-A2 on the metastasis of colorectal cancer using artificial (experimental) and spontaneous metastasis of Colon 26 tumor cells" 08/01/2001 - "The goal of this article is to review the features of the main oral 5-FU prodrugs, which include capecitabine, uracil and tegafur (UFT)/leucovorin, S-1, and BOF-A2 and to describe their potential efficacy in treating colorectal cancer." Get all the results and reference details, order at left...
4.	Neoplasms (Cancer) 10/01/2000 - "PURPOSE: To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of emitefur (BOF-A2) in patients with advanced solid tumors" 10/01/2000 - "Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors." 08/01/1994 - "BOF-A2 was expected to be a promising new anti-cancer agent in the future clinical trial." 02/01/1993 - "Antitumor effects of BOF-A2 given intermittently was evaluated with human gastric (H-111, H-83), colorectal (H-110, H-143) and lung (H-74, LC-376) cancers xenografted in nude mice and compared with those by continuous administration" 09/01/1990 - "Twenty-five consecutive oral administration of BOF-A2 at 17.5 to 30 mg/kg over 4 weeks caused marked inhibition or regression (over 92% of inhibition rate) to the growth of H-81, H-143 and H-31 cancers" Get all the results and reference details, order at left...
5.	Yoshida Sarcoma 02/01/1989 - "The ED50 (the dose for 50% inhibition) values of BOF-A2 were 25 mg/kg against sarcoma-180 and 15 mg/kg against Yoshida sarcoma" 02/01/1989 - "The antitumor activity of BOF-A2 was investigated in sarcoma-180-bearing mice and Yoshida sarcoma-bearing rats" 07/01/1987 - "BOF-A1 and BOF-A2, new compounds combined with CNDP were markedly active against mouse sarcoma 180 and rat Yoshida sarcoma." 02/01/1989 - "After oral administration of BOF-A2 at 15 mg/kg to Yoshida sarcoma-bearing rats, BOF-A2 was hydrolyzed to EM-FU, CNDP and 5-FU, and their maximum concentrations in the blood were 2000 ng/ml, 300 ng/ml and 40 ng/ml, respectively" Get all the results and reference details, order at left...
17 Diseases and 22 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	Uracil
3.	Tegafur
4.	Prodrugs
5.	Leucovorin (Folinic Acid)
6.	capecitabine (Xeloda)
7.	Emitefur
8.	2,6-dihydroxy-3-cyanopyridine
9.	1-ethoxymethyl-5-fluorouracil
10.	irinotecan (Camptosar)
22 Drugs and Important Bio-Agents and 21 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Adjuvant Chemotherapy
2.	Heterologous Transplantation (Xenotransplantation)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Drug Therapy (Chemotherapy)
4 Therapies and Procedures and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>